Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) attributable profit jumped 21% to 4.55 billion yuan in 2024 from 3.77 billion yuan in 2023, according to a Thursday filing with the Hong Kong bourse.
The Chinese pharmaceutical company's earnings per share rose to 1.23 yuan from 1.02 yuan a year earlier.
Operating income edged up 5.75% to 275.3 billion yuan from 260.3 billion yuan a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.